Soliton Selects RESONIC as Brand Name for FDA-Cleared Rapid Acoustic Pulse Device
The initial launch of the RESONIC brand for tattoo and cellulite indications is expected in Q2 of 2021.
The initial launch of the RESONIC brand for tattoo and cellulite indications is expected in Q2 of 2021.
The injectable treatment showed a 30-percentage-point advantage over placebo in submental fat responder rates after a single treatment cycle, supporting plans for a regulatory filing in China by year-end.